Mitochondrial Alteration
10
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Nicotinamide Riboside in LVAD Recipients
National CounterACT Initiative
Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort
High Intensity Interval Training and Muscle Adaptations During PR
The Impact of Covid-19 on Skeletal Muscle
Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Mitochondrial Energy Metabolism in Obese Women